Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease, focused on therapies targeting soluble amyloid-beta oligomers. Its lead candidate, sabirnetug, is a monoclonal antibody designed to bind and neutralize these oligomers and is being… From the company’s description.
In fiscal 2025, Acumen Pharmaceuticals, Inc. reported a net loss of $121.33M. Operations used $115.54M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Acumen Pharmaceuticals, Inc. does
In the company’s own words
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease, focused on therapies targeting soluble amyloid-beta oligomers. Its lead candidate, sabirnetug, is a monoclonal antibody designed to bind and neutralize these oligomers and is being evaluated in a Phase 2 trial in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The company is also developing an oligomer-targeted therapy designed to cross the blood-brain barrier, including through a collaboration with JCR Pharmaceuticals, and a subcutaneous formulation of sabirnetug with Halozyme. Acumen has no product approved for commercial sale and contracts with third parties to manufacture sabirnetug; its business is centered on research and development rather than commercial product operations. In 2025, it reported a collaboration with JCR to develop up to two candidates using JCR’s J-Brain Cargo® technology. Acumen’s website is https://www.acumenpharm.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEWTON, MA
- Fiscal year end
- December
- CIK
- 1576885
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Acumen Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Acumen Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Acumen Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Acumen Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Acumen Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”